Pins matching company:Pfizer

On 23 August 2021 the FDA approved Comirnaty, the Pfizer-BioNTech COVID-19 vaccine, for people 16 and older, making it the first approved COVID-19 vaccine and the first approved mRNA therapy in the US.

On 14 December 2023 Pfizer completed its acquisition of cancer biotech Seagen for US$229 per share in cash, an enterprise value of about US$43 billion, and donated US Bavencio royalties to AACR to address FTC concerns.

On 30 September 2025 Pfizer announced an agreement with the Trump administration to price drugs in line with other developed countries and sell through TrumpRx.gov, pledging a further US$70 billion in US investment.

On 13 November 2025 Pfizer completed its acquisition of obesity biotech Metsera for US$65.60 per share in cash, an enterprise value of about US$7.0 billion, plus a contingent value right of up to US$20.65 per share.

On 4 August 2026 Pfizer reported second-quarter revenue of US$15.0 billion, adjusted EPS of US$0.77 and a US$4.3 billion impairment charge, and raised full-year revenue guidance by US$500 million.

Pfizer's phase 3 trial of Ibuzatrelvir in covid-19 sars-cov-2 infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,330 participants. The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.

Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question.

Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups.